MyAverix Finance
TA · Healthcare
Lineage Cell Therapeutics, Inc. (LCTX)
Biotechnology
Lineage Cell Therapeutics, Inc. (LCTX) is listed on TA in the Healthcare sector. Industry: Biotechnology. As of 2026-05-24, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.
Key metrics for LCTX
Lineage Cell Therapeutics, Inc. (LCTX) — FAQ
What is LCTX's P/E ratio?
The price-to-earnings (P/E) ratio for Lineage Cell Therapeutics, Inc. (LCTX) is 25.00 (data as of 2026-05-24).
Does Lineage Cell Therapeutics, Inc. pay a dividend?
Dividend yield is not available in the current snapshot for Lineage Cell Therapeutics, Inc. (LCTX). Check the MyAverix Finance app for the latest dividend data.
What sector is Lineage Cell Therapeutics, Inc. in?
Lineage Cell Therapeutics, Inc. (LCTX) is classified in the Healthcare sector (Biotechnology industry).
What exchange is LCTX listed on?
LCTX is listed on TA.
Full report in the app
Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.